| 1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
|
| 2 |
Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer[J]. Lancet, 2014, 384(9951):1376-1388.
|
| 3 |
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4):284-296.
|
| 4 |
Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary[J]. Cancer Res, 2005, 65(22):10602-10612.
|
| 5 |
Earp M, Tyrer JP, Winham SJ, et al. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility[J]. PLoS One, 2018, 13(7):e0197561.
|
| 6 |
Urban RR, Pappas TC, Bullock RG, et al. Bullock RG et al:combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass[J]. Gynecol Oncol, 2018, 150(2):318-323.
|
| 7 |
US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.[J]. JAMA, 2018, 319(6):588-594.
|
| 8 |
Gamwell LF, Collins O, Vanderhyden BC. The mouse ovarian surface epithelium contains a population of LY6A (SCA-1) expressing progenitor cells that are regulated by Ovulation-Associated factors[J]. Biol Reprod, 2012, 87(4):80.
|
| 9 |
Flesken-Nikitin A, Hwang CI, Cheng CY, et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche[J]. Nature, 2013, 495(7440):241-245.
|
| 10 |
McCloskey CW, Goldberg RL, Carter LE, et al. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population[J]. Front Oncol, 2014, 4:53.
|
| 11 |
Roberts PC, Mottillo EP, Baxa AC, et al. Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model[J]. Neoplasia, 2005, 7(10):944-956.
|
| 12 |
Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration [J]. Nucleic Acids Res, 2013, 41(Database issue):D808-D815.
|
| 13 |
Saito R, Smoot ME, Ono K, et al. A travel guide to Cytoscape plugins[J]. Nat Methods, 2012, 9(11):1069-1076.
|
| 14 |
Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome Atlas (TCGA): an immeasurable source of knowledge[J]. Contemp Oncol (Pozn), 2015, 19(1A):A68-A77.
|
| 15 |
Győrffy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer[J]. PLoS One, 2013, 8(12):e82241.
|
| 16 |
Kurose K, Zhou XP, Araki T, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas[J]. Am J Pathol, 2001, 158(6):2097-2106.
|
| 17 |
Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer[J]. Arch Gynecol Obstet, 2014, 290(6):1067-1078.
|
| 18 |
Rössig L, Jadidi AS, Urbich C, et al. Akt-dependent phosphorylation of p21(Cip1)regulates PCNA binding and proliferation of endothelial cells[J]. Mol Cell Biol, 2001, 21(16):5644-5657.
|
| 19 |
Roby KF, Taylor CC. Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer[J]. Carcinogenesis, 2000, 21(4):585-591.
|
| 20 |
Roberts PC, Schmelz EM. In vitro model of spontaneous mouse OSE transformation[J]. Methods Mol Biol, 2013, 1049:393-408.
|
| 21 |
Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research[J]. Front Oncol, 2013, 3:256.
|
| 22 |
Ricci F, Broggini M, Damia G. Revisiting ovarian cancer preclinical models: Implications for a better management of the disease[J]. Cancer Treat Rev, 2013, 39(6):561-568.
|
| 23 |
Campbell IG, Russell SE. Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer[J]. Cancer Res, 2004, 64(21):7678-7681.
|
| 24 |
Che YL, Luo SJ, Li G, et al. The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis[J]. Cancer Lett, 2015, 359(2):241-249.
|
| 25 |
Hanahan D, Weinberg RA. The hallmarks of cancer[J]. Cell, 2000, 100(1):57-70.
|
| 26 |
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer[J]. Nature, 2001, 411(6835):342-348.
|
| 27 |
Reddy BA, van der Knaap JA, Bot AG, et al. Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization[J]. Mol Cell, 2014, 53(3):458-470.
|
| 28 |
Holzer K, Drucker E, Roessler S, et al. Proteomic analysis reveals GMP synthetase as p53 repression target in liver cancer[J]. Am J Pathol, 2017, 187(2):228-235.
|
| 29 |
Jönsson JM, Skovbjerg Arildsen N, Malander S, et al. Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival[J]. Transl Oncol, 2015, 8(5):424-433.
|
| 30 |
Lee P, Rosen DG, Zhu C, et al. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer[J]. Gynecol Oncol, 2005, 96(3):671-677.
|
| 31 |
Lenhard M, Tereza L, Heublein S, et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival[J]. BMC Cancer, 2012, 12:553.
|
| 32 |
Sieh W, Köbel M, Longacre TA, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study[J]. Lancet Oncol, 2013, 14(9):853-862.
|
| 33 |
Feng Z, Wen H, Bi R, et al. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression[J]. Sci Rep, 2016, 6:25408.
|
| 34 |
Tangjitgamol S, Manusirivithaya S, Khunnarong J, et al. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study[J]. Int J Gynecol Cancer, 2009, 19(4):620-627.
|
| 35 |
van Kruchten M, van der Marel P, de Munck L, et al. Hormone receptors as a marker of poor survival in epithelial ovarian cancer[J]. Gynecol Oncol, 2015, 138(3):634-639.
|
| 36 |
Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis[J]. Int J Gynecol Pathol, 2007, 26(4):404-409.
|
| 37 |
Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity[J]. Annu Rev Immunol, 1998, 16:111-135.
|
| 38 |
Van Kooten C, Banchereau J. CD40-CD40 ligand[J]. J Leukoc Biol, 2000, 67(1):2-17.
|
| 39 |
Qin L, Qiu H, Zhang M, et al. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment[J]. Biomed Pharmacother, 2016, 79:166-175.
|
| 40 |
Zhou Y, He J. Gou LT, et al. Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells[J]. Cancer Immunol Immunother, 2012, 61(10):1735-1743.
|
| 41 |
Xiong Y, Gj H. Zhang H, et al. p21 is a universal inhibitor of cyclin kinases[J]. Nature, 1993, 366(6456):701-704.
|
| 42 |
Alves MR, E Melo NC, Barros-Filho MC, et al: Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma[J]. Cancer Med. 2018. doi: 10.1002/cam4.1530.
|
| 43 |
Shang D, Wu Y. Ding Y, et al. Identification of a pyridine derivative inducing senescence in ovarian cancer cell lines via P21 activation[J]. Clin Exp Pharmacol Physiol, 2018, 45(5):452-460.
|
| 44 |
Cheng X, Xia W. Yang JY, et al. Activation of p21(CIP1/WAF1)in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis[J]. Biochem Biophys Res Commun, 2010, 403(1):103-107.
|
| 45 |
Hawthorne VS, Huang WC. Neal CL, et al. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells[J]. Mol Cancer Res, 2009, 7(4):592-600.
|
| 46 |
Liu X, Yu H. Cai H, et al. Expression of CD24, p21, p53, and c-myc in alpha-fetoprotein-producing gastric cancer:correlation with clinicopathologic characteristics and survival[J]. J Surg Oncol, 2014, 109(8):859-864.
|
| 47 |
Taghavi N, Biramijamal F, Sotoudeh M, et al. Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients[J]. World J Gastroenterol, 2010, 16(39):4958-4967.
|